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1. Introduction 
Helicobacter pylori (HP) is recognized as a major pathogenic factor for persistent inflammation 
in the human stomach (Dooley et al., 1989; Marshall & Warren, 1984). In 1994, the International 
Agency for Research on Cancer (IARC) classified HP infection as a definite class I carcinogen 
(International Agency for Research on Cancer (IARC), 1994). HP triggers chronic inflammation 
of the infected stomach mucosa and is considered a major risk factor for gastric cancer (GC) 
and associated precursor lesions. Long-lasting inflammation in the stomach mucosa leads to a 
cascade of molecular and morphological changes, representing the gastritis-atrophy-
metaplasia-dysplasia-cancer sequence (Correa, 1992). The HP infection rate is higher in Japan 
than in Western countries, with nearly all cases of GC occurring in subjects with underlying 
HP-related chronic gastritis. HP infection is widely accepted as a major risk factor for the 
development of GC and its precursor lesions, based on extensive evidence derived from many 
studies (Blaser et al., 1995; EUROGAST Study Group, 1993; Forman et al., 1991; Hirayama et 
al., 1999; Honda et al., 1998; Huang et al., 1998; Nomura et al., 1991; Parsonnet et al., 1991; 
Shimizu et al., 1999; Sipponen et al., 1992; Sugiyama et al., 1998; Talley et al., 1991; Tokieda et 
al., 1999; Uemura et al., 2001; Watanabe et al., 1998; Zheng et al., 2004). 
However, in countries such as Japan, where the HP infection rate is high, prediction of GC 
risk based solely on the presence or absence of HP infection does not offer sufficient 
specificity. Elucidation of groups at high risk based on the natural history of GC is clearly 
necessary. The identification of useful markers of GC risk is thus hoped for. Evaluating HP-
related chronic gastritis and determining which subjects are at high risk for developing GC 
is very important, and would likely increase the efficacy of GC screening by endoscopic or 
other examinations (Enomoto et al., 2010a; Mukoubayashi et al., 2007; Ohata et al., 2005), 
and strategic approaches to metachronous multiple GC after endoscopic mucosal resection 
(EMR) or endoscopic submucosal dissection (ESD) performed as minimally invasive 
treatment for early GC (Gotoda, 2007; Kakushima & Fujishiro, 2008; Nakajima et al., 2006). 
In addition, in terms of GC prevention, it has become clear that HP-related chronic gastritis 
cannot be ignored as an origin of carcinogenesis. 
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Here, we discuss the significance of serum pepsinogen (PG) as a marker of GC risk and GC 
high-risk groups based on HP-related chronic gastritis. We also discuss the prevention for 
individuals with HP-related chronic gastritis.  
2. GC risk diagnosis based on the natural history of HP-related chronic 
gastritis 
Novel risk markers to identify GC high-risk groups based on a detailed natural history of 
HP-related chronic gastritis have long been awaited. In this section, we discuss the emerging 
significance of serum PG as a GC risk marker for more precise identification of GC high-risk 
groups. 
2.1 Serum PG test 
HP-related chronic gastritis usually starts in the antrum and expands proximally towards 
the body of the stomach (Kimura, 1972; Tatsuta et al., 1973). As several studies dealing with 
endoscopic biopsies or chromoendoscopic testing have found that progression of chronic 
atrophic gastritis (CAG) increases the risk of cancer (Meister et al., 1979; Sipponen et al., 
1985; Siurala et al., 1966; Tatsuta et al., 1993; Testoni et al., 1987), accurate and reliable 
evaluation of the extent of CAG is considered important for identifying individuals at high 
risk of cancer. However, accurately diagnosing the extent of CAG based on a few biopsy 
samples is difficult, because CAG together with intestinal metaplasia is a multifocal process. 
Furthermore, histological diagnosis of gastric atrophy depends on subjective judgment 
without a gold standard (Guarner et al., 1999; Plummer et al., 1997). A test for CAG 
progression that is more convenient, free of discomfort or risk, economical and based on 
objective parameters is needed. 
PG is the inactive precursor of pepsin, a digestive enzyme specifically produced in the 
stomach. Immunologically, two isozymes exist (Kageyama, 2003). PGI is produced by chief 
cells and mucus neck cells of the gastric fundic glands. In contrast, PGII is produced not 
only by chief cells and mucus neck cells, but also in cardiac glands, pyloric glands, and 
Brunner’s glands, with localization of producing cells in a wide range from the stomach to 
the duodenum. The majority of PG produced (about 99%) is secreted in the stomach lumen 
and functions as a digestive enzyme. However, a small amount of PG (about 1%) is also 
present in blood and can be evaluated by measuring serum PG levels. Serum PG levels are 
generally agreed to reflect the morphological and functional status of the stomach mucosa 
(Hirschowitz, 1957; Samloff et al., 1982). 
In an endoscopic study with Congo red staining, we have shown a strong correlation 
between an increase in glandular boundary, associated with diagnosed progression of 
gastric mucosal atrophy, and stepwise reductions in serum PGI levels and the PGI/PGII 
ratio (Fig. 1) (Miki et al., 1987). In other words, by measuring serum PGI and the PGI/II 
ratio, the progression of CAG, which is involved in GC carcinogenesis, can be objectively 
evaluated (Ichinose et al., 2001). In addition, during HP infection, serum PGI and PGII 
increase, and the PG I/II ratio decreases. These findings are improved after eradication 
treatment (Furuta et al., 1997) and are useful as gastric mucosal inflammatory markers. 
Several criteria are used in the serum PG test. As criteria for GC screening, the combination 
of PGI ≤70 ng/ml and PGI/II ratio ≤3.0, as a reference value by Miki et al., is widely 
accepted (PG index 1+) (Ichinose et al., 2001; Watanabe et al., 1997). Values lower than this 
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Fig. 1. Relationship between serum pepsinogen (PG)I/PGII ratio and progression of chronic 
atrophic gastritis (CAG). With atrophic changes in the gastric mucosa progressing from the 
pyloric glands to more proximally, the serum PGI/II ratio decreases, reflecting an associated 
loss of PG-producing cells. CAG, chronic atrophic gastritis; SE, standard error. 
reference value are considered PG-test positive. In addition to this reference value, to 
identify more severe CAG progression, criteria of PGI ≤50 ng/ml and PGI/II ratio ≤3.0 (PG 
index 2+), and PGI ≤30 ng/ml and PGI/II ratio ≤2.0 (PG index 3+) are also used. Since 1992, 
when PG assay kits became commercially available, a number of screening services 
provided by workplaces or community health services have adopted this serum test as a 
filter test (Hattori et al., 1995; Kitahara et al., 1999; Kodoi et al., 1995; Miki et al., 1993; Miki et 
al., 2003; Ohata et al, 2005; Yoshihara et al., 1997). However, the long-term prognosis of 
subjects with extensive CAG identified by PG filter test is not fully known. 
2.2 Detection accuracy of GC using the serum PG test 
We conducted a large-scale cohort study spanning more than 10 years in Wakayama 
Prefecture, Japan, and identified groups at high risk for GC (Ohata et al., 2004; Yanaoka et 
al., 2008a; Yanaoka et al., 2008b). Based on the results, accuracy of each criteria of the serum 
PG test for GC that occurred during the observation period was evaluated (Yanaoka et al, 
2008a). Accuracy of the criteria is shown in Table 1. For the most favorable criteria (PG 
index 1+), sensitivity was 58.7%, specificity was 73.4%, and positive predictive value was 
2.6%. Compared to a meta-analysis of PG test sensitivity (Dinis-Ribeiro et al., 2004), these 
results were poor, particularly in terms of sensitivity. 
As a reason for these poor results, the presence of GC easy to detect by barium X-ray, and 
GC easy to detect by the serum PG test, was cited (Ohata et al, 2005). In the above-
mentioned meta-analysis, many of the previously reported cases that were reviewed were 
from studies in populations in which GC screening by conventional barium X-ray had been 
conducted over a period of many years. In other words, that study reviewed results for GC 
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PGI ≤70 and PGI/II ≤3 PGI ≤50 and PGI/II ≤3 PGI ≤30 and PGI/II ≤2
[PG index 1+] [PG index 2+] [PG index 3+]
Meta-analysis of reported cases
(Dinis-Ribeiro et al., 2004)
Pooled sensitivity 77.3% 68.4% 51.9%
(95%CI) (69.8-83.8) (59.1-76.8)  (40.3-63.5)
Pooled specificity 73.2% 69.3% 84.4%
(95%CI) (72.8-73.6)  (66.6-70.0) (83.7-85.0)
Our results
(Yanaoka et al., 2008a)
Sensitivity 58.7% 49.2% 27.0%
(95%CI) (45.6-70.8) (36.5-62.0) (16.9-39.9)
Specificity 73.4% 80.5% 92.0%
(95%CI) (72.1-74.6) (79.4-81.6%) (91.3-92.8)
PG, pepsinogen. 
CI, confidential interval.
Serum PG test criteria
 
Table 1. Comparison of accuracy for each criterion in the serum PG test. 
detection just after introduction of the serum PG test, over a short period, and targeting a 
population in whom GC was difficult to detect by barium X-ray, i.e., those in whom GC was 
easy to detect by the serum PG test. On the other hand, GC cases just after introduction of 
the serum PG test were excluded from our study, and observation was over a long period of 
10 years. Accordingly, results for the detection of GC occurring during the observation 
period were more rigorously evaluated, and thus more correctly reflective of the accuracy 
for detecting GC by the serum PG test. Based on the above results, using the serum PG test 
alone for GC screening has limitations. A more elaborate system must therefore be 
developed, including for GC screening in PG test-negative cases. 
2.3 GC risk in a serum PG test-positive group 
Previous studies have examined the accuracy of the serum PG test as a filter test for 
endoscopy. Recently, as part of an investigation into the natural history of GC occurrence, 
we evaluated GC risk in populations identified by each criteria for the serum PG test 
(Yanaoka et al, 2008a). In a population of middle-aged healthy men, in an atrophy-negative 
group, the annual incidence of GC was 0.07%. In contrast, annual incidence was 0.28% in the 
PG index 1+ group, 0.32% in the PG index 2+ group, and 0.42% in the PG index 3 +group, 
showing significant stepwise increases in GC incidence with CAG progression (Fig. 2) Based 
on these results, PG test-positive groups, as assumed, are high-risk groups for GC. In other 
words, an individual who is serum PG test-positive, even if GC is not currently detectable, 
still has a high possibility of developing GC in the future. Careful monitoring with detailed 
testing is clearly indicated in such subjects. This again demonstrates the usefulness of the PG 
test as a marker of high risk for GC. 
2.4 Natural history of HP-related chronic gastritis and GC risk 
In addition to the serum PG test, the natural history of HP-related chronic gastritis and 
associations with GC risk have been examined by evaluating HP infection, as the major 
cause of onset and progression of chronic gastritis in Japan (Ohata et al, 2004; Yanaoka et al, 
2008b). HP infection is diagnosed using anti-HP antibody titers, which, like the serum PG 
test, is a blood test that is easy to perform. The stages of HP-related chronic gastritis, from 
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Fig. 2. Kaplan-Meier analysis of gastric cancer development in subjects classified using the 
criteria of the serum pepsinogen (PG) test. Among middle-aged healthy men, annual 
incidence of gastric cancer is shown for each population identified using various criteria for 
the serum PG test. Progression of chronic atrophic gastritis showed a significant stepwise 
increase in the incidence of gastric cancer. 
the onset of HP infection to development of atrophic gastritis, can be classified based on a 
combination of both serum blood tests: Group A [HP(-), PG(-)], Group B [HP(+), PG(-)], 
Group C [HP(+), PG(+)], and Group D [HP(-), PG(+)]. Group A comprised HP non-infected 
healthy subjects. Group B showed established HP infection, but without extensive CAG. 
Group C had extensive CAG. Group D had severe intestinal metaplasia due to progression 
of CAG, but HP had been spontaneously eliminated, representing so-called metaplastic 
gastritis. 
The natural history of HP-related chronic gastritis from the onset of HP infection can be 
shown to progress from each stage: A→B→C→D. Based on a follow-up study, the annual 
incidence of GC for each group using this stage classification was: 0% for Group A (no 
occurrence of GC during 10 years in this group); 0.11% for Group B (GC in 1 per 1000 
patients per year); 0.24% for Group C (GC in 1 per 400 patients per year); and 1.31% for 
Group D (GC in about 1 per 80 patients per year). Based on these data, with progression in 
stage of HP-related chronic gastritis, a stepwise increase is seen for GC incidence (Fig. 3). 
Similar results were reported by Watabe et al. (Watabe et al., 2005). During the 10-year 
follow-up study, all patients who developed GC were HP infection-positive. These results 
showed that in Japan, almost all cases of GC are associated with HP-related chronic gastritis. 
Theoretically, based on this fact, not only a GC high-risk group, but also a GC low-risk 
group (group A), can be identified. This is expected to contribute greatly to suitable and 
more intensive GC screening. 
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Fig. 3. Gastric cancer risk and prevention of gastric cancer based on Helicobacter pylori (HP)-
related chronic gastritis stage. This shows the stage classification for HP-related chronic 
gastritis based on the serum pepsinogen (PG) test and HP antibodies. Among middle-aged 
healthy men, the annual incidence of gastric cancer showed a significant stepwise increase 
from Group A to Group D according to stage progression. Regarding gastric cancer 
prevention based on stage, in Group B, with mild atrophy, prevention of gastric cancer 
mainly by HP eradication can be expected. In Group D, with progression of atrophy and 
metaplastic gastritis, prevention of gastric cancer mainly by administration of non-steroidal 
anti-inflammatory drugs (e.g., cyclooxygenase 2 inhibitors) can be expected. In addition, 
prevention of gastric cancer may be possible with dietary habits. 
2.5 Points in the diagnosis of GC risk using the serum PG test 
The serum PG test is clearly a highly useful test for a GC risk marker. However, the 
occurrence of GC (particularly diffuse-type GC) in PG test-negative groups (group B in the 
stage classification for HP-related chronic gastritis) cannot be ignored. In our study, even 
when using the PG test criteria considered as the most balanced in terms of test accuracy 
(PG index 1+), the fact remains that about 40% of GC cases are PG test-negative. When 
diagnosing GC risk using the serum PG test, this fact must be carefully considered. 
We therefore carefully investigated GC occurrence in a PG test-negative group. Specifically, 
to evaluate GC incidence, we subdivided the PG test-negative group into 3 groups: ǂ group 
(serum PGI ≤70 ng/ml and PGI/II >3); ǃ group (serum PGI >70 ng/ml and PGI/II >3), and 
Ǆ group (serum PGI >70 ng/ml and PGI/II ≤3). The results identified a new group at high 
risk of GC, with GC incidence in the Ǆ group (high serum PGII levels and severe 
inflammation of the gastric mucosa) reaching 0.2%, predominantly involving 
undifferentiated GC (Yanaoka et al, 2008a). This rate in the Ǆ group, although not 
necessarily high among the PG test-negative group, still indicates a subgroup that deserves 
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particular attention. In addition, a group with high HP antibody titer (a marker that, like 
serum PGII level, reflects severity of inflammation) showed higher incidence of GC 
compared to a low-titer group (Yanaoka et al, 2008b).  
Among PG test-negative groups, in group A of the stage classification for HP-related 
chronic gastritis (PG test-negative and HP-negative), we observed no occurrence of GC over 
a 10-year follow-up period. However, some cautionary points must be considered in a 
confirmatory diagnosis of Group A status. First, with HP antibody assay kits showing low 
sensitivity, antibody titers may be negative despite prior HP infection. Second, in HP-
negative cases after eradication therapy, it should be kept in mind that “although HP is 
negative, the risk of GC is not zero.” Third, risk assessment by the serum PG test cannot be 
applied in subjects with post-gastrectomy ,with renal insufficiency, using proton pump 
inhibitors, or showing an acute gastric mucosal lesion (AGML). In addition, we have 
reported that in subjects with a PGI/II ratio ≤3.0, serum PGI ≤30 ng/ml, or serum PGII >30 
ng/ml, the risk of GC is significantly higher (Yanaoka et al, 2008b). Based on these data, 
even among group A patients, if the PGI/II ratio is ≤3.0 or serum PGI is ≤30 ng/ml, 
endoscopy should be performed once to evaluate the possible presence of CAG. 
3. Prevention of GC based on the natural history of HP-related chronic 
gastritis 
The evaluation of HP-related chronic gastritis is especially important in the analysis of GC 
prevention. However, previous studies have not assessed the extent of coexisting CAG or 
have assessed it only with endoscopic findings and/or histopathology on endoscopic 
biopsy. In this section, we discuss the strategy of GC prevention according to the evaluation 
of HP-related chronic gastritis based on the serum PG test. 
3.1 Prevention of GC by HP eradication 
Many previous studies have been conducted on the inhibition of GC by eradication therapy 
for HP, a major factor in gastric carcinogenesis. HP eradication therapy has recently been 
shown to prevent metachronous cancer after endoscopic resection of early GC (Fukase et al., 
2008). However, in several reports to date, the effects on prevention of GC have not been as 
clear-cut as the effects of HP eradication on prevention of peptic ulcers. The studies that 
found inhibitory effects on gastric carcinogenesis were often non-randomized studies with a 
short observation period of ≤5 years (Fuccio et al., 2007). Moreover, results have been mixed. 
For example, in studies of GC occurrence after HP eradication in groups with or without 
precancerous lesions (CAG or intestinal metaplasia), significant inhibition of GC in the 
without-precancerous-lesion group was reported (Take et al., 2007; Wong et al., 2004). On 
the other hand, absence of inhibition of GC, regardless of the presence or absence of 
precancerous lesions, has also been reported (You et al., 2006). In contrast, in an animal 
study using HP-infected Mongolian gerbils, inhibition of gastric carcinogenesis by HP 
eradication was clearly demonstrated (Tatematsu et al., 2007). 
These study results suggest several points. First, inhibition of gastric carcinogenesis by HP 
eradication is not complete, and even after eradication, more than a few GC cases have been 
observed. Second, the earlier during infection that eradication therapy is started, the greater 
the inhibitory effect on GC. Third, after a duration has elapsed, irreversible changes due to 
HP infection develop, representing a “point of no return”. This suggests an attenuated 
www.intechopen.com
 
Gastritis and Gastric Cancer – New Insights in Gastroprotection, Diagnosis and Treatments 
 
186 
eradication effect. Fourth, HP infection promotes the proliferation and growth of cancer cells 
that have already developed (promoter effect). During long-term observation, clear-cut 
inhibition of gastric carcinogenesis by HP eradication is not seen, but eradication groups 
with shorter observation periods may display apparent inhibition of GC, with slower 
growth rates, and without growth of cancer that can be clinically diagnosed. Fifth, besides 
promoter effects on GC, HP infection, as previously described in detail, is also involved in 
gastric carcinogenesis mediated through the development and progression of CAG and 
intestinal metaplasia. To achieve a reduction in GC risk by eradication, in addition to HP 
elimination, improvement of CAG and intestinal metaplasia is necessary. 
Based on these points, when evaluating the prevention of GC by HP eradication, evaluation of 
the equivalence of GC risk in the eradication group and non-eradication group (control) is 
necessary. With regard to this point, in almost all previous studies, either evaluation of CAG 
progression has been lacking, or even if evaluated, endoscopic or histopathologic findings, 
with strong subjective elements, were used. We therefore conducted a 10-year follow-up study 
in middle-aged healthy adults in whom progression of atrophic gastritis was monitored by 
serum PG (Yanaoka et al., 2009). In that study, although non-randomized, both the HP 
eradication and control groups showed equivalence with regard to CAG progression (an 
important risk factor), in addition to major risk factors for GC such as age, gender, and 
smoking. In this study, no significant inhibition of GC was observed even with HP eradication. 
However, with assessment by the PG test, evaluation in the PG test-positive (extensive 
CAG) and PG test-negative (non-extensive CAG) groups showed that HP eradication in the 
PG test-positive group did not prevent GC, whereas HP eradication in the PG test-negative  
group only achieved significant inhibition of GC (Fig. 4). These results confirm the  
 
 
Fig. 4. Kaplan-Meier analysis of the proportion of subjects free of gastric cancer in the serum 
pepsinogen (PG) test-positive group and the PG test-negative group according to 
Helicobacter pylori (HP) infection status. In the serum PG test-positive group (extensive 
chronic atrophic gastritis (CAG)), no reduction in gastric cancer incidence was observed 
with HP eradication. Only the PG test- negative group (non-extensive CAG) showed a 
reduction in gastric cancer incidence with HP eradication. 
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previously mentioned results that assumed that no significant prevention of GC by HP 
eradication was achieved due to advanced CAG. This strongly suggests that in the majority 
of PG test-positive subjects, the stomach is past the “point of no return.” The significance of 
HP eradication thus lies in achieving: 1) a decrease in GC proliferation and growth rates by 
inhibiting the GC-promoting effects of HP; 2) inhibition of carcinogenesis by halting 
progression of CAG; and 3) inhibition of inflammation-based gastric carcinogenesis 
(particularly diffuse-type GC) by healing chronic active gastritis. In fact, our study also 
showed that diffuse-type GC can be significantly inhibited by HP eradication. 
3.2 Chemoprevention of GC by NSAIDs 
Although prevention of GC by HP eradication can be expected, from a more realistic 
perspective, the effectiveness may be somewhat limited. In particular, among patients with 
advanced CAG, the chemopreventive effects of HP eradication therapy alone are unlikely to 
be sufficient. In populations where inhibition of gastric carcinogenesis cannot be achieved 
by HP eradication therapy alone, chemoprevention with the use of non-steroidal anti-
inflammatory drugs (NSAIDs) is promising as a treatment strategy. Cyclooxygenase (COX) 
is a rate-limiting enzyme of prostaglandin synthesis in the arachidonic acid cascade. Among 
COX isozymes, attention has been focused on inducible COX-2, which is expressed in 
inflammatory responses and cancer proliferation (Kujubu et al., 1991). COX-2 expression has 
been reported in many gastrointestinal cancers, including colorectal cancer (Eberhart et al., 
1994), and research has been undertaken into the prevention of carcinogenesis by COX-2 
regulation (Giardiello et al., 1993; Kawamori et al., 1998; Kune et al., 1988; Thun et al., 1991). 
With regard to COX-2 expression in the gastric mucosa, not only a high rate of COX-2 
expression in GC cells, but also COX-2 expression in precancerous lesions such as CAG, 
intestinal metaplasia, and dysplasia has been reported (Sung et al., 2000). In a study of GC 
tissue types, a high rate of COX-2 expression was found in intestinal-type GC (Saukkonen et 
al., 2001). In a study of GC according to site, cancers of the gastric cardia showed decreased 
COX-2 expression compared to cancers of other gastric areas (Ratnasinghe et al., 1999). In 
epidemiologic and animal studies, long-term use of aspirin or other NSAIDs has been 
reported to decrease GC risk in a dose-dependent manner (Duan et al., 2008; Hu et al., 2004; 
Wang et al., 2003). 
In a Mongolian gerbil model of chronic active gastritis, which closely resembles HP-related 
chronic gastritis in humans, we evaluated the effects of etodolac, a selective COX-2 inhibitor, 
after initiation with a low dose of N-methyl-N-nitrosourea, a chemical carcinogen (Magari et 
al., 2005). The results confirmed that treatment with etodolac early in HP infection 
completely inhibited gastric carcinogenesis, which usually occurs at a high rate. In this 
model, we confirmed that proliferation of gastric mucosal epithelial tissue was significantly 
inhibited by etodolac, and that the development of intestinal metaplasia, thought to be a 
precancerous lesion, was significantly inhibited. In addition, we conducted a clinical study 
of GC chemoprevention using a COX-2 inhibitor in patients with metaplastic gastritis 
(Yanaoka et al., 2010). This study, although non-randomized, included patients who had 
undergone endoscopic resection of intestinal-type GC with a background of metaplastic 
gastritis. The incidence of metachronous cancer was evaluated in etodolac and non-
treatment groups during a mean observation period of 4.2 years. The diagnosis of 
metaplastic gastritis was based on serum testing, as previously described. Regarding HP-
related chronic gastritis stage, these patients were classified as Group D [HP(-), PG(+)]. In 
this study, long-term treatment with etodolac as a selective COX-2 inhibitor effectively 
inhibited metachronous cancer development in curatively treated, early GC patients with 
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metaplastic gastritis. These results are in line with the results of our previous animal 
experiment using HP-infected Mongolian gerbils, indicating that etodolac can prevent 
stomach carcinogenesis involving the CAG-metaplasia-dysplasia-cancer sequence. Serious 
cardiovascular events, depending on the drug, have been reported with long-term 
administration of COX-2 inhibitors. Whether etodolac is the best choice requires further 
investigation. However, particularly among patients with extensive CAG, in addition to HP 
eradication therapy, aggressive chemoprevention using NSAIDs such as selective COX-2 
inhibitors may effectively inhibit gastric carcinogenesis (Fig. 3). 
3.3 Possible GC prevention by dietary habits 
On the other hand, HP eradication therapy and chemoprevention using NSAIDs were not 
carried out in all subjects, as problems exist with adverse effects of HP eradication or 
chemoprevention, drug-resistant bacteria, and medical economics. Research into HP-related 
chronic gastritis and promoters and inhibitors of gastric carcinogenesis, and studies of 
alternative therapies, primarily in the form of functional foods, has thus been conducted. In 
the progression of HP-related chronic gastritis, besides HP virulence factors such as VacA 
and CagA (Hatakeyama, 2004), and host factors such as cytokine polymorphisms (El-Omar 
et al., 2000), environmental factors such as lifestyle and dietary habits have been shown to 
be involved. In particular, dietary factors have been highly implicated as the factors to 
which the gastric mucosa is most frequently and directly exposed. For example, high 
sodium intake increases gastric mucosal inflammation and the risk of gastric cancer (Nozaki 
et al., 2002; Shikata et al., 2006) and cigarette smoking is considered to be deeply involved in 
the transition of CAG to intestinal metaplasia and dysplasia (Kneller et al., 1992; Tredaniel et 
al., 1997), which are precancerous conditions, in a model of gastric carcinogenesis postulated 
by Correa (Correa and Houghton, 2007). On the other hand, epidemiologic and animal 
studies have found that vegetables, fruits, and green tea can inhibit gastritis and reduce 
gastric carcinogenesis (Kobayashi et al., 2002; Yu et al., 1995). 
The Japanese apricot (JA) (ume in Japanese; Prunus mume Siebold et Zucc.), in extracted or 
pickled form, has long been empirically used in Japan as a folk remedy for gastrointestinal 
infections such as gastroenteritis. In an in vitro study, Fujita et al. reported that JA extract 
displayed bactericidal activity against HP (Fujita et al., 2002). In addition, in an animal study 
using Mongolian gerbils, Otsuka et al. showed in vivo anti-HP effects of JA extract, 
demonstrating inhibition of chronic gastritis in HP-infected Mongolian gerbils (Otsuka et al., 
2005). Based on these reports, because of the presumably potent anti-HP effects of JA, we 
conducted a study on associations between regular consumption of JA and HP-related 
chronic gastritis (Enomoto et al., 2010b; Jones, 2010). As a result, we found that consumption 
of JA is effective in inhibiting HP-related active inflammation of the stomach and CAG 
progression, and that development of GC may be inhibited by JA intake. Of course, because 
dietary habits are greatly influenced by other lifestyle factors, depending on the population 
being studied, the effectiveness achieved in preventing GC may differ. However, promoting 
dietary habits that protect against GC, including JA intake, may be an ideal alternative 
strategy for GC prevention (Fig. 3). 
4. Conclusion 
In conclusion, based on the natural history of HP-related chronic gastritis from blood test 
data, including the serum PG test and HP antibodies, specific prediction of the risk of GC in 
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each individual is now possible. With this information, more effective strategies to prevent 
GC are becoming possible. These are anticipated to have clinical applications such as in 
more effective GC screening, and in establishing appropriate GC prevention. 
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